Jeong-Eun Lee

Jeong-Eun Lee

Auto-generated profile, based on publicly available information

Jeong-Eun Lee

Department of Molecular Medicine, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 700-422, Republic of Korea

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2011 in Proteomics
Verified
Journal Article
Closed access
PDF file
PMPyong‐Gon Moon
Pyong‐Gon Moon
JLJeong‐Eun Lee
Jeong‐Eun Lee
SYSungyong You
Sungyong You
TKTaek‐Kyun Kim
Taek‐Kyun Kim
JCJi‐Hoon Cho
Ji‐Hoon Cho
MBMoon-Chang Baek
Moon-Chang Baek

31 March 2016 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PMPyong-Gon Moon
Pyong-Gon Moon
JLJeong-Eun Lee
Jeong-Eun Lee
YCYoung-Eun Cho
Young-Eun Cho
SLSoo Jung Lee
Soo Jung Lee
JJJin Hyang Jung
Jin Hyang Jung
MBMoon-Chang Baek
Moon-Chang Baek
Purpose: Currently, there are no molecular biomarkers for the early detection of breast cancer. This study focused on identifying surface proteins found on circulating extracellular vesicles (EVs) for detecting early-stage breast cancer. Experimental Design: Circulating EVs, isolated from the plasma of 10 patients with breast cancer (stages I and II) and 5 healthy controls, were analyzed using LC-MS/MS. Developmental endothelial locus-1 protein (Del-1) was selected as a candidate biomarker. Two different ELISAs were used to measure Del-1 in plasma samples from healthy controls (n = 81), patients with breast cancer (n = 269), breast cancer patients after surgical resection (n = 50), patients with benign breast tumors (n = 64), and patients with noncancerous diseases (n = 98) in two cohorts. Results: Plasma Del-1 levels were significantly higher (P < 0.0001) in patients with breast cancer than in all controls and returned to almost normal after tumor removal. The diagnostic accuracy of Del-1 was AUC, 0.961 [95% confidence interval (CI), 0.924–0.983], sensitivity of 94.70%, and specificity of 86.36% in test cohort and 0.968 (0.933–0.988), 92.31%, and 86.62% in validation cohort for early-stage breast cancer by one type of ELISA. Furthermore, Del-1 maintained diagnostic accuracy for patients with early-stage breast cancer using the other type of ELISA [0.946 (0.905–0.972), 90.90%, and 77.14% in the test cohort; 0.943 (0.900–0.971), 89.23%, and 80.99% in the validation cohort]. Conclusions: Del-1 on circulating EVs is a promising marker to improve identification of patients with early-stage breast cancer and distinguish breast cancer from benign breast tumors and noncancerous diseases. Clin Cancer Res; 22(7); 1757–66. ©2015 AACR.

23 May 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
PMPyong-Gon Moon
Pyong-Gon Moon
JLJeong-Eun Lee
Jeong-Eun Lee
YCYoung-Eun Cho
Young-Eun Cho
SLSoo Jung Lee
Soo Jung Lee
YCYee Soo Chae
Yee Soo Chae
MBMoon-Chang Baek
Moon-Chang Baek
Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer

1 January 2016 in Journal of Proteomics
Verified
Journal Article
Closed access
JLJeong-Eun Lee
Jeong-Eun Lee
PMPyong-Gon Moon
Pyong-Gon Moon
YCYoung-Eun Cho
Young-Eun Cho
YKYoung-Bum Kim
Young-Bum Kim
IKIn-San Kim
In-San Kim
MBMoon-Chang Baek
Moon-Chang Baek

22 May 2015 in The Protein Journal
Verified
Journal Article
Closed access
PDF file
JLJeong-Eun Lee
Jeong-Eun Lee
PMPyong-Gon Moon
Pyong-Gon Moon
ILIn-Kyu Lee
In-Kyu Lee
MBMoon-Chang Baek
Moon-Chang Baek

1 January 2012 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
YCYoung-Eun Cho
Young-Eun Cho
TSThoudam S. K. Singh
Thoudam S. K. Singh
HLHyun-Chul Lee
Hyun-Chul Lee
PMPyong-Gon Moon
Pyong-Gon Moon
JLJeong-Eun Lee
Jeong-Eun Lee
MBMoon-Chang Baek
Moon-Chang Baek
Cisplatin is used widely for treatment of a variety of cancer diseases. Recently, however, the use of cisplatin is restricted because of its adverse effects such as hepatotoxicity. There is no study with current proteomics technology to evaluate cisplatin-induced hepatotoxicity, even if some studies have reported on the hepatotoxicity. In this study, proteomic as well as genomic analyses have been used for identification of proteins and genes that respond to cisplatin treatment in rat primary hepatocytes. To investigate the hepatotoxic effects of cisplatin, rat primary hepatocytes were treated with an IC20 concentration for 24 h. From proteomic analysis based on label-free quantitation strategy, cisplatin induced 76 up-regulated and 19 down-regulated proteins among 325 distinct proteins. In the mRNA level, genomic analysis revealed 72 up-regulated and 385 down-regulated genes in the cisplatin-treated group. Based on these two analyses, 19 pathways were commonly altered, whereas seven pathways were identified only by proteomic analysis, and 19 pathways were identified only by genomic analysis. Overall, this study explained the mechanism of cisplatin-induced hepatotoxicity with two points of view: well known pathways including drug metabolism, fatty acid metabolism, and glycolysis/TCA cycle and little known pathways including urea cycle and inflammation metabolism, for hepatotoxicity of other toxic agents. Up-regulated proteins detected by proteomic analysis in the cisplatin-treated group: FBP1 (fructose 1,6-bisphosphatase 1), FASN (fatty acid synthase), CAT (catalase), PRDX1 (peroxiredoxin-1), HSPD1 (60-kDa heat shock protein), MDH2 (malate dehydrogenase 2), and ARG1 (arginase 1), and also down-regulated proteins in the cisplatin-treated group: TPM1 (tropomyosin 1), TPM3 (tropomyosin 3), and CTSB (cathepsin B), were confirmed by Western blot analysis. In addition, up-regulated mRNAs detected by microarray analysis in the cisplatin-treated group: GSTA2, GSTT2, YC2, TXNRD1, CYP2E1, CYP2C13, CYP2D1, ALDH17, ARG1, ARG2, and IL-6, and also down-regulated mRNAs: CYP2C12, CYP26B1, TPM1, and TPM3, were confirmed by RT-PCR analysis. In case of PRDX1, FASN, and ARG1, they were further confirmed by immunofluorescence analysis. Through the integrated proteomic and genomic approaches, the present study provides the first pathway map related to cisplatin-induced hepatotoxicity, which may provide new insight into the mechanism of hepatotoxicity.